早期前列腺素E1治疗可改善视网膜中央动脉闭塞患者的视力:一项回顾性研究。

IF 0.9
Frontiers in ophthalmology Pub Date : 2025-08-20 eCollection Date: 2025-01-01 DOI:10.3389/fopht.2025.1665519
Hiroki Sano, Ryoji Yanai, Hirotaka Kondo, Yoshinori Mitamura
{"title":"早期前列腺素E1治疗可改善视网膜中央动脉闭塞患者的视力:一项回顾性研究。","authors":"Hiroki Sano, Ryoji Yanai, Hirotaka Kondo, Yoshinori Mitamura","doi":"10.3389/fopht.2025.1665519","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Central retinal artery occlusion (CRAO) is a vision-threatening emergency with no established effective treatment. Prostaglandin E<sub>1</sub> (PGE<sub>1</sub>), known for its vasodilatory and cytoprotective properties, may offer therapeutic benefits for retinal ischemia.</p><p><strong>Methods: </strong>In this retrospective study, we compared visual outcomes between CRAO patients who received intravenous PGE<sub>1</sub> within 24 hours of symptom onset (followed by oral administration) and those who received conventional therapy. PGE<sub>1</sub> was administered intravenously for 5 days.</p><p><strong>Results: </strong>At one month, the PGE<sub>1</sub> group showed significantly better best-corrected visual acuity compared to the control group. Baseline structural retinal parameters, including maximal retinal thickness (MRT) and central retinal thickness (CRT), did not differ significantly between groups. In the PGE<sub>1</sub> group, baseline MRT was negatively correlated with visual acuity at one month. Retinal arteriovenous diameters showed no significant change post-treatment. No adverse events were observed in either group.</p><p><strong>Conclusion: </strong>Early administration of PGE<sub>1</sub> may improve visual outcomes in CRAO. These findings support further investigation into PGE<sub>1</sub> as a potential treatment for acute retinal ischemia.</p>","PeriodicalId":73096,"journal":{"name":"Frontiers in ophthalmology","volume":"5 ","pages":"1665519"},"PeriodicalIF":0.9000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404978/pdf/","citationCount":"0","resultStr":"{\"title\":\"Early prostaglandin E<sub>1</sub> treatment improves visual outcomes in central retinal artery occlusion: a retrospective study.\",\"authors\":\"Hiroki Sano, Ryoji Yanai, Hirotaka Kondo, Yoshinori Mitamura\",\"doi\":\"10.3389/fopht.2025.1665519\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Central retinal artery occlusion (CRAO) is a vision-threatening emergency with no established effective treatment. Prostaglandin E<sub>1</sub> (PGE<sub>1</sub>), known for its vasodilatory and cytoprotective properties, may offer therapeutic benefits for retinal ischemia.</p><p><strong>Methods: </strong>In this retrospective study, we compared visual outcomes between CRAO patients who received intravenous PGE<sub>1</sub> within 24 hours of symptom onset (followed by oral administration) and those who received conventional therapy. PGE<sub>1</sub> was administered intravenously for 5 days.</p><p><strong>Results: </strong>At one month, the PGE<sub>1</sub> group showed significantly better best-corrected visual acuity compared to the control group. Baseline structural retinal parameters, including maximal retinal thickness (MRT) and central retinal thickness (CRT), did not differ significantly between groups. In the PGE<sub>1</sub> group, baseline MRT was negatively correlated with visual acuity at one month. Retinal arteriovenous diameters showed no significant change post-treatment. No adverse events were observed in either group.</p><p><strong>Conclusion: </strong>Early administration of PGE<sub>1</sub> may improve visual outcomes in CRAO. These findings support further investigation into PGE<sub>1</sub> as a potential treatment for acute retinal ischemia.</p>\",\"PeriodicalId\":73096,\"journal\":{\"name\":\"Frontiers in ophthalmology\",\"volume\":\"5 \",\"pages\":\"1665519\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404978/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/fopht.2025.1665519\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fopht.2025.1665519","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:视网膜中央动脉闭塞(CRAO)是一种威胁视力的急症,目前尚无有效的治疗方法。前列腺素E1 (PGE1)以其血管扩张和细胞保护特性而闻名,可能对视网膜缺血有治疗作用。方法:在这项回顾性研究中,我们比较了在症状出现24小时内静脉注射PGE1(随后口服)和接受常规治疗的CRAO患者的视力结果。PGE1静脉滴注5天。结果:1个月时,PGE1组最佳矫正视力明显优于对照组。基线视网膜结构参数,包括最大视网膜厚度(MRT)和中央视网膜厚度(CRT),组间无显著差异。在PGE1组中,基线MRT与一个月时的视力呈负相关。治疗后视网膜动静脉直径无明显变化。两组均未观察到不良事件。结论:早期应用PGE1可改善cro患者的视力。这些发现支持进一步研究PGE1作为急性视网膜缺血的潜在治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Early prostaglandin E<sub>1</sub> treatment improves visual outcomes in central retinal artery occlusion: a retrospective study.

Early prostaglandin E<sub>1</sub> treatment improves visual outcomes in central retinal artery occlusion: a retrospective study.

Early prostaglandin E<sub>1</sub> treatment improves visual outcomes in central retinal artery occlusion: a retrospective study.

Early prostaglandin E1 treatment improves visual outcomes in central retinal artery occlusion: a retrospective study.

Background: Central retinal artery occlusion (CRAO) is a vision-threatening emergency with no established effective treatment. Prostaglandin E1 (PGE1), known for its vasodilatory and cytoprotective properties, may offer therapeutic benefits for retinal ischemia.

Methods: In this retrospective study, we compared visual outcomes between CRAO patients who received intravenous PGE1 within 24 hours of symptom onset (followed by oral administration) and those who received conventional therapy. PGE1 was administered intravenously for 5 days.

Results: At one month, the PGE1 group showed significantly better best-corrected visual acuity compared to the control group. Baseline structural retinal parameters, including maximal retinal thickness (MRT) and central retinal thickness (CRT), did not differ significantly between groups. In the PGE1 group, baseline MRT was negatively correlated with visual acuity at one month. Retinal arteriovenous diameters showed no significant change post-treatment. No adverse events were observed in either group.

Conclusion: Early administration of PGE1 may improve visual outcomes in CRAO. These findings support further investigation into PGE1 as a potential treatment for acute retinal ischemia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信